泌尿器科領域におけるCefodizime (THR-221) の基礎的・臨床的検討

DOI

書誌事項

タイトル別名
  • EXPERIMENTAL AND CLINICAL INVESTIGATION OF CEFODIZIME (THR-221) IN UROLOGY

抄録

We experimentally and clinically investigated cefodizime (THR-221), a newly developed injectable antibiotic.<BR>The serum level was studied in rabbits under dehydration and overhydration after a bolus i. v. injection of 1 g of THR-221. There was no distinct difference in serum level between dehydration and overhydration.<BR>In a clinical study, 2 g of THR-221 b.i.d. was given by i.v. drip infusion for several days to 3 patients with chronic complicated cystitis and 4 with chronic complicated cystitis + acute prostatitis. Efficacy was excellent in 1 patient, moderate in 4 and poor in 2 according to the criteria of the UT! Committee. The efficacy rate was 71.4%.<BR>Efficacy was also excellent in 1 patient each with acute uncomplicated pyelonephritis and acute prostatitis, and good in 1 with acute prostatitis+acute epididymitis according to the doctor's evaluation. No adverse reactions or objective and subjective signs occurred.<BR>A slight elevation of GPT occurred in 2 patients, but improved after withdrawal of the drug.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ